The results indicated that there was a pathological stage-specific expression level of ADRA2C in BRCA, esophageal adenocarcinoma (ESCA), KIRP, and lung squamous cell carcinoma (LUSC) (Figures 2A, 2B, 2C and 2D, p<0.05). This evidence concerns the gene ADRA2C and squamous cell lung carcinoma.